Merck announced the US launch of RENFLEXIS, a biosimilar for Remicade

[Jim Rogers]

Merck today announced the US launch of RENFLEXIS, a biosimilar for Remicade, which was approved by FDA for all eligible indications. RENFLEXIS will have a wholesale acquisition cost of $753.39, which is a 35% discount compared to Remicade. However, wholesale costs do not include discounts. As per the QuintilesIMS data, Remicade was the fifth bestselling drug in the US in 2016 raking in $5.3Bil on an invoice price basis.
http://alph.st/b4671819